Literature DB >> 27010220

Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization.

Amanda J H Gilliam1, Joshua N Smith1, Dylan Flather1, Kevin M Johnston1, Andrew M Gansmiller1, Dmitry A Fishman1, Joshua M Edgar1, Mark Balk1, Sudipta Majumdar1, Gregory A Weiss1.   

Abstract

Caveolin-1 is a target for academic and pharmaceutical research due to its many cellular roles and associated diseases. We report peptide WL47 (1), a small, high-affinity, selective disrupter of caveolin-1 oligomers. Developed and optimized through screening and analysis of synthetic peptide libraries, ligand 1 has 7500-fold improved affinity compared to its T20 parent ligand and an 80% decrease in sequence length. Ligand 1 will permit targeted study of caveolin-1 function.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27010220      PMCID： PMC5529100          DOI： 10.1021/acs.jmedchem.5b01536

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  34 in total

1.  A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo.

Authors:  A Schlegel; M P Lisanti
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

2.  Spot synthesis: observations and optimizations.

Authors:  A Kramer; U Reineke; L Dong; B Hoffmann; U Hoffmüller; D Winkler; R Volkmer-Engert; J Schneider-Mergener
Journal:  J Pept Res       Date:  1999-10

3.  Double barrel shotgun scanning of the caveolin-1 scaffolding domain.

Authors:  Aron M Levin; Katsuyuki Murase; Pilgrim J Jackson; Mack L Flinspach; Thomas L Poulos; Gregory A Weiss
Journal:  ACS Chem Biol       Date:  2007-06-29       Impact factor: 5.100

4.  Regulation of caveolin and caveolae by cholesterol in MDCK cells.

Authors:  D Hailstones; L S Sleer; R G Parton; K K Stanley
Journal:  J Lipid Res       Date:  1998-02       Impact factor: 5.922

Review 5.  Caveolin-1, cellular senescence and age-related diseases.

Authors:  Huafei Zou; Elena Stoppani; Daniela Volonte; Ferruccio Galbiati
Journal:  Mech Ageing Dev       Date:  2011-11-12       Impact factor: 5.432

6.  Cells respond to mechanical stress by rapid disassembly of caveolae.

Authors:  Bidisha Sinha; Darius Köster; Richard Ruez; Pauline Gonnord; Michele Bastiani; Daniel Abankwa; Radu V Stan; Gillian Butler-Browne; Benoit Vedie; Ludger Johannes; Nobuhiro Morone; Robert G Parton; Graça Raposo; Pierre Sens; Christophe Lamaze; Pierre Nassoy
Journal:  Cell       Date:  2011-02-04       Impact factor: 41.582

Review 7.  Caveolins and caveolae, roles in insulin signalling and diabetes.

Authors:  Peter Strålfors
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection.

Authors:  Ara G Hovanessian; Jean-Paul Briand; Elias A Said; Josette Svab; Stephane Ferris; Hayet Dali; Sylviane Muller; Claude Desgranges; Bernard Krust
Journal:  Immunity       Date:  2004-11       Impact factor: 31.745

9.  Lipid rafts, caveolae, caveolin-1, and entry by Chlamydiae into host cells.

Authors:  Elizabeth S Stuart; Wilmore C Webley; Leonard C Norkin
Journal:  Exp Cell Res       Date:  2003-07-01       Impact factor: 3.905

10.  Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies.

Authors:  Ronit Shaltiel-Karyo; Moran Frenkel-Pinter; Nirit Egoz-Matia; Anat Frydman-Marom; Deborah E Shalev; Daniel Segal; Ehud Gazit
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240
View more
  1 in total

1.  Directed evolution and biophysical characterization of a full-length, soluble, human caveolin-1 variant.

Authors:  Joshua N Smith; Joshua M Edgar; J Mark Balk; Mariam Iftikhar; Jessica C Fong; Tivoli J Olsen; Dmitry A Fishman; Sudipta Majumdar; Gregory A Weiss
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2018-05-29       Impact factor: 3.036
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.